White Paper
Delivering value and efficiencies beyond traditional FSP resourcing
Consider the opportunity to reshape outsourcing and better leverage service providers
Jan 25, 2021

The pharmaceutical industry faces continued pressure to reduce cost and improve speed of new medicines development, as well as adapt to the ever-changing global regulatory landscape. The cost of drug development continues to rise and is doing so at a rate that is outpacing the expected growth in net revenue for pharmaceutical companies. This is an unsustainable scenario; one that will require industry leaders to re-examine the nature of the enterprise required for future success in this changing marketplace.

Large, multi-national pharmaceutical firms use extensive internal infrastructure to support the development of therapies. While use of third-party providers has allowed flexibility in approaches to staffing capabilities like clinical monitoring or safety reporting, many have continued to rely upon ownership of internal processes and systems.

With increasing pressure on profitability, competitiveness, and the need to accelerate development, many have turned to Software-as-a-Service (SaaS) solutions to simplify the management of their information technology infrastructure in the rapidly evolving landscape surrounding drug development. Yet, most continue to be challenged to integrate these solutions into the existing framework of how work is accomplished within the enterprise and keep pace with the changing landscape of clinical development innovation.

Perhaps, rather than continuing to own the processes and systems that comprise a functional capability even when the work is largely supported by third-party provided resources, one could consider the strategic bundling of resources, processes, and technology managed within the third-party organizations.

Related solutions

Contact Us